Abstract
An 8-week, nonrandomized, single-blind, placebo run-in trial of sertraline was conducted on 15 patients diagnosed with major depression between 3 and 24 months after a mild traumatic brain injury. On the Hamilton Rating Scale for Depression, 13 (87%) had a decrease in score of > or = 50% ("response"), and 10 (67%) achieved a score of < or = 7 ("remission") by week 8 of sertraline. There was statistically significant improvement in psychological distress, anger and aggression, functioning, and postconcussive symptoms with treatment.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antidepressive Agents, Second-Generation / therapeutic use*
-
Brain Concussion / complications*
-
Brain Concussion / psychology
-
Depressive Disorder / drug therapy*
-
Depressive Disorder / etiology*
-
Depressive Disorder / psychology
-
Female
-
Health Status Indicators
-
Humans
-
Male
-
Middle Aged
-
Pilot Projects
-
Psychiatric Status Rating Scales
-
Selective Serotonin Reuptake Inhibitors / therapeutic use*
-
Sertraline / therapeutic use*
-
Sickness Impact Profile
Substances
-
Antidepressive Agents, Second-Generation
-
Serotonin Uptake Inhibitors
-
Sertraline